| Company Overview |  |
|
|
Hepaguard Company Group (HCG) is an Asian R&D-based
pharmaceutical & biotechnological company with a powerful combination
of skills and resources that provides a platform for delivering strong
growth in today’s rapidly changing healthcare environment.
The Hepaguard Group was founded in 1996 and was formed by the association of Hepaguard Company Limited (Korea), Hepaguard (Int’l) Company Limited (Hong Kong, SAR), and Hepaguard Biotechnology (Int’l) Company Limited (Taiwan, ROC). With the attention focused on the development of natural medicines and treatments for Hepatitis B, the Hepaguard Group has been working cooperatively in research and develops new cures for one of the most devastating diseases in Asia. |
||
 |
The
current primary objective of Hepaguard Group is to be Asia’s leading
enterprise specializing in the development of new herbal treatments
for Hepatitis. The three associated companies approach this goal in
a joint venture structure. Hepaguard (Korea) is responsible for preclinical
/ clinical studies and the research & development of Hepaguard Trademark
products. Hepaguard (Hong Kong) and Hepaguard (Taiwan) are both responsible
for the sales & marketing in the Asian markets, while Hepaguard
(Taiwan) is also responsible for further research and development of
new and existing products. |
|
